Sun Young Rha

researcher

Sun Young Rha is …
instance of (P31):
humanQ5

External links are
P496ORCID iD0000-0002-2512-4531

P106occupationresearcherQ1650915

Reverse relations

author (P50)
Q50565053A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.
Q40690113A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
Q42770955A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Q59296874A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
Q36832238A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
Q79329265A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation
Q50318351A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report.
Q51356279A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer.
Q38821431A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
Q46130279A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.
Q39827658A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.
Q84090042A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
Q82267815A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status
Q43281047A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
Q36612624A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Q34051972A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
Q84794314A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer
Q43689423A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Q84372123A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis
Q83979395A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
Q33399177A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Q38731875ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition.
Q51666682ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer.
Q40211834Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression.
Q40113468An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Q33502227An attempt for combining microarray data sets by adjusting gene expressions
Q34657590Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
Q87814813Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer
Q39928916Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
Q37650644Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
Q34444374Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
Q46324182Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
Q47775732Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy
Q82210847Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
Q81025165Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells
Q61800297Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Q57463137BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
Q92817469Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients
Q29620647Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
Q80730909Bilateral breast cancer: differential diagnosis using histological and biological parameters
Q36067835Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients
Q33577959Brain metastases from colorectal carcinoma: prognostic factors and outcome.
Q48208260Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
Q41959108Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
Q57221322Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients
Q41186107Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates.
Q58542491Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer
Q80320197Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
Q41145098Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.
Q38505143Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Q85823325Changing treatment patterns in elderly patients with resectable colon cancer
Q35472842Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium
Q42172414Characterizing the outcomes of metastatic papillary renal cell carcinoma
Q84788817Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
Q100387543Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
Q39822963Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients.
Q33619223Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee
Q53517909Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma.
Q34354224Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Q37065537Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia
Q37376890Clinical value of ezrin expression in primary osteosarcoma.
Q34494770Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites.
Q53250755Clinicopathological features and prognostic significance of HER2 expression in gastric cancer.
Q104500409Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis
Q34054383Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure.
Q33395803Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Q33888813Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
Q37536970Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.
Q37376227Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
Q38894275Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.
Q55400516CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer.
Q53641389Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy.
Q46678519Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss.
Q35188542Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Q37123409DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers
Q59115813Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation
Q33761681Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab
Q92299126Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial
Q39203035Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
Q58600783Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma
Q38332631Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction.
Q40320758Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma.
Q33557905Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia
Q39401605Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma.
Q48689595Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.
Q54577559Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Q33576276Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials
Q38189898Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Q36348040EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.
Q64284309EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction
Q45816663Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer.
Q57211074Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma
Q37367458Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.
Q33410008Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.
Q50090476Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Q82367592Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis
Q34669352Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
Q50953072Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma.
Q37315416Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity
Q37696106Epstein-Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells.
Q53175509Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Q83831946Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes
Q34086969External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Q59296888External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
Q37110135Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma
Q27851960Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
Q33749070Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Q37711680First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Q34183978First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium
Q36961529Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference.
Q50050277Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Q39698913Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms.
Q80376888Gastrointestinal stromal tumor of the rectum: an analysis of seven cases
Q33365840Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
Q100519389Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
Q47844242Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions
Q33296347Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization
Q39612136Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis.
Q33781926Green tea consumption and stomach cancer risk: a meta-analysis.
Q80555453Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines
Q33990397High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
Q38838849High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
Q38469106Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer
Q34356765Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
Q39729921Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Q38305699Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer.
Q53456797Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray.
Q33495849Identification of significant regional genetic variations using continuous CNV values in aCGH data.
Q38197606Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
Q57068038Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
Q34007924Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy
Q33343730Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions
Q39937932In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.
Q34977196Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
Q79195955Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma
Q38493648Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer.
Q44417564Infusional Fluorouracil, Etoposide, and Cisplatin (FEP) in Advanced and Relapsed Gastric Cancer
Q35777894Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study
Q39358547Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer
Q59115799Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer
Q46911437Intermediate dose 5-fluorouracil-induced encephalopathy.
Q35154288Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy
Q33795207Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case
Q42876509Kidney Cancer Working Group report.
Q47273213Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas.
Q52716996Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
Q53525146Leiomyosarcoma: investigation of prognostic factors for risk-stratification model
Q91249826Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
Q36292688Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer.
Q55608179Long-term survival after surgical resection for liver metastasis from gastric cancer: two case reports.
Q38867037Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation
Q88780568MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
Q90553378Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial
Q36500021Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
Q38706540Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines.
Q40942600Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer.
Q51911503Molecular basis of the differences between normal and tumor tissues of gastric cancer.
Q53462601Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia
Q43614958Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer.
Q80375798Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
Q45959241Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Q33375134Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Q59330587Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
Q35152348Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer
Q31116686Novel and simple transformation algorithm for combining microarray data sets.
Q34193096Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis
Q33361612OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
Q37357165Oncogenic pathway combinations predict clinical prognosis in gastric cancer.
Q41755706Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Q91347054Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Q34138032Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Q34428153Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
Q38945020PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity.
Q36832212PTEN Methylation Dependent Sinonasal Mucosal Melanoma
Q27853081PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.
Q47838777PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
Q30417878Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report
Q33410206Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Q36872919Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.
Q33384540Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Q33503003Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study
Q57222268Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
Q41508355Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma
Q46755330Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer.
Q53247583Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Q54494004Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
Q53458025Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
Q33397403Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Q45093247Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Q44130825Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.
Q39850176Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer.
Q81800649Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials
Q38422833Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery.
Q34966145Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
Q83811955Prediction of recurrence of early gastric cancer after curative resection
Q38410346Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
Q43828828Prevalence and associated factors of psychological distress among Korean cancer patients.
Q33587575Prevalence and prognostic implications of psychological distress in patients with gastric cancer
Q41200095Prevalence of human papillomavirus infection and RAS mutation in sporadic keratoacanthoma.
Q37316735Prognosis of pN3 stage gastric cancer.
Q37015759Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience
Q50847454Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Q36230768Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
Q79456937Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute
Q36072022Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Q37269360Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
Q45308745Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
Q49206365Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
Q55026328Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer.
Q38720296Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
Q38382303Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.
Q39909656Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer
Q48626617Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer.
Q49679541Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin.
Q36065419Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Q90473923Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial
Q37687784Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm
Q57299791Reconsideration of sample size and power calculation for overall survival in cancer clinical trials
Q38803935Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration
Q33919180Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer
Q39668099Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Q59352012Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer
Q36782534Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity.
Q59794754Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
Q36187013Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Q39861038Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
Q37133691Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis.
Q40278455Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Q86632070Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell
Q46845089Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Q49348813S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
Q41907282S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer.
Q33345613SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis.
Q54462541Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
Q35233550Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Q36374816Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.
Q93096106Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma
Q91014807Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy
Q33396613Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
Q80785552Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases
Q34896252Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
Q47597183Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life.
Q96827775Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells
Q39439368Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor.
Q37596836Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.
Q46427241Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells.
Q93183045Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Q38832501The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control.
Q53607051The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer.
Q35561464The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Q89285151The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer
Q38484252The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Q79999473The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
Q34646724The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression
Q83201457The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer
Q36872857The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma
Q34081616The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
Q40252205The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
Q39067669The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation
Q53201331The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status.
Q34612189The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas.
Q44537561Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.
Q40419339Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents.
Q104792688Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
Q43958960Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.
Q84871530Treatment of recurrent hepatocellular carcinoma after liver transplantation
Q33385981Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea
Q91695726Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
Q51195343Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density.
Q33566877Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer
Q91567210Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients
Q52965644Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer.
Q50670233Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study.
Q35877763Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.
Q53539819Whole genome analysis for liver metastasis gene signatures in colorectal cancer.
Q53263421hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness.
Q36482470p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer

Search more.